DALLAS, Nov. 3, 2016 /PRNewswire/ -- Gradalis, Inc., a clinical-stage biopharmaceutical company focused on developing Vigil® engineered autologous tumor cell (EATC) immunotherapy, will participate in the 22nd Annual BIO Europe Conference. The conference is being held November 7-9 in Cologne, Germany.
"Gradalis is actively seeking collaboration partners for geographic rights to Vigil EATC Cellular Immunotherapy," said Mr. Sunil Joshi, President and Chief Executive Officer, Gradalis. "With registrational studies underway in Ewing's sarcoma and ovarian cancer, Gradalis intends to engage other pharmaceutical and biotechnology companies to discuss development and commercialization of Vigil in US and Ex-US markets."
Partnering requests to Gradalis may be made through the BIO Europe partnering portal, or directly to Mr. Scott Generes at firstname.lastname@example.org. Mr. Joshi will be available for meetings during the conference from November 7 through November 9, 2016.
About BIO Europe: More information about BIO Europe may be found at their website www.ebdgroup.knect365.com/bioeurope/
About Gradalis: Gradalis is a fully integrated biotechnology company based in Dallas, Texas that focuses on the development, manufacturing, and commercialization of novel proprietary personalized cellular immunotherapies to treat cancer. Gradalis operates a cGMP manufacturing facility in Carrolton, Texas. For more information about Gradalis, Inc. visit us at www.gradalisinc.com, follow us on Twitter or on Facebook.
About Vigil EATC: Vigil is an investigational cellular immunotherapy technology that combines the concepts of genetic engineering with the science of immuno-oncology, to enable an immune response to cancer cells. A patient's tumor cells are engineered with a plasmid carrying the gene vector for shRNA Furin and GMCSF to elicit a systemic T-cell directed immune response when administered to the patient through intradermal injections. By utilizing the patient's own tumor as the antigen source, Vigil EATC is designed to elicit an immune response that is specifically targeted and broadly relevant to each patient's unique tumor antigens. Vigil EATC is being studied in Ewing's sarcoma and ovarian cancer as a single agent, and in breast cancer, non-small cell lung cancer and melanoma in combination with PD1 and PD-L1 inhibitors. More information about these studies can be found at www.vigilclinicaltrials.com.
Gradalis® and Vigil® are registered trademarks of Gradalis, Inc.
Chief Financial Officer